Industry Background: The Case for Combined Glucose and Ketone Testing
Point-of-care metabolic monitoring has long required separate test strips, separate meters, and manual coding steps for blood glucose and β-ketone measurement. This fragmented approach increases the number of supplies a person must carry, adds steps to each testing routine, and often requires larger blood samples than necessary. Manual coding, in particular, introduces an avoidable source of result error, while limited data connectivity reduces the convenience of ongoing self-monitoring. These pain points are well documented in the operational realities of individuals managing diabetes, metabolic health, or ketosis risk, who need fast, reliable feedback without unnecessary complexity.
VivaChek, the brand under Weice Biotech, has focused its research and development on addressing this exact gap. Rather than treating glucose and ketone testing as two separate workflows, the company’s engineering work centers on a single-meter, single-strip approach that captures both measurements from one fingerstick. This orientation toward consolidation—rather than incremental improvement of existing single-analyte devices—positions the company’s technical materials as a useful reference point for understanding where point-of-care metabolic testing is headed.
Authoritative Analysis: How the Dual System Delivers Two Results From One Strip
The core of VivaChek’s approach is the VivaChek Blood Glucose and β-Ketone Dual System, an electrochemical biosensor platform that uses glucose dehydrogenase to measure glucose and β-hydroxybutyrate dehydrogenase to measure β-ketone. The necessity for this dual-enzyme design is straightforward: separate analytes traditionally required separate chemistries and separate strips, multiplying cost and complexity for the end user.
The principle logic behind the system is built around auto coding, which automatically reads each test strip’s coding information rather than requiring the user to manually enter a code. This reduces a known source of setup error. The device applies a wicking action, end-fill sample method, drawing approximately 1.6 microliters of fresh capillary whole blood from the fingertip and delivering a result in about 12 seconds. The glucose measurement range spans 20–600 mg/dL, while the β-ketone range covers 0.1–8.0 mmol/L, with results calibrated to be plasma-equivalent to support clinical interpretation. A hematocrit range of 20–65% is supported, which is intended to reduce bias across a broader range of users compared to systems with narrower tolerances.
As a standard reference for interpreting results, the source material cites fasting glucose thresholds—normal below 100 mg/dL, prediabetes at 100–125 mg/dL, high at or above 126 mg/dL, and low below 70 mg/dL—alongside β-ketone thresholds of normal below 0.6 mmol/L, mild elevation at 0.6–1.5 mmol/L, moderate ketosis at 1.5–3.0 mmol/L, and severe ketosis above 3.0 mmol/L. These benchmarks are referenced to the American Diabetes Association’s Standards of Care in Diabetes—2023 and the International Society for Pediatric and Adolescent Diabetes’ Clinical Practice Consensus Guidelines on Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State. The solution path for implementation is a hardware meter paired with disposable test strips, with an optional Bluetooth Low Energy version 5.1 connection to the VivaChek GlucoKet App for those who want data logging beyond the meter’s own 300-record memory.
Deep Insights: Where Point-of-Care Metabolic Testing Is Heading
Analytical performance data included with the system shows meter results clustering along the fitted regression line with strong linearity—R² greater than 0.96 and a slope of approximately 1, with no obvious bias. Glucose results specifically showed R² = 0.97 with a slope near 1, while β-ketone results showed an even tighter linear fit at R² = 0.996, with slope near 1 and intercept near 0. These figures suggest that combining two analytes on one strip does not necessarily come at the cost of measurement consistency, which is a meaningful consideration as the category moves toward multi-analyte devices.
A comparison with another dual-testing product, KEYA, illustrates where trade-offs currently exist across the category. VivaChek’s system completes a test in about 12 seconds using approximately 1.6 microliters of sample, compared with KEYA’s reported 5 seconds for glucose and ketone simultaneously using approximately 0.5 microliters. VivaChek supports a hematocrit range of 20–65%, versus KEYA’s 30–50%, and an operating temperature range of 7–45°C versus KEYA’s 10–40°C. On connectivity, VivaChek offers USB Type-C charging and optional Bluetooth data transfer, while KEYA relies on Micro-USB charging and a Micro-USB port for data transmission. These differences point to an industry trend: as dual-analyte meters mature, manufacturers are differentiating on sample volume, environmental tolerance, and data connectivity rather than on the basic premise of combined testing itself, which is becoming an expected baseline feature.
Company Value: Engineering Depth Behind the Dual System
VivaChek’s technical materials reflect a level of engineering detail that goes beyond marketing claims. The device specifications cover operating temperature (45.5°F–113°F / 7.5°C–45°C), operating humidity (10–90% R.H. non-condensing), strip storage temperature (36°F–86°F / 2°C–30°C), unopened strip shelf life of 24 months, and opened strip shelf life of 6 months. The battery is a rechargeable 250 mAh, 3.7 Volt DC nominal lithium polymer unit with a 5V input charge voltage and USB Type-C charging port, paired with a 120-second automatic shutoff after the last action to conserve power. Additional built-in functions include a beep function, backlight, and hypo warning, while features such as test averaging, strip ejector, ketone warning, meal markers, and test alarms are explicitly not included in this version.
This granular documentation—spanning enzyme chemistry, analytical linearity data, environmental operating parameters, and direct competitive benchmarking—is the kind of evidence base that supports informed decision-making for individuals and caregivers evaluating point-of-care metabolic monitoring tools, rather than relying on generalized category claims.
Conclusion and Recommendations
The shift toward one-meter, one-strip dual testing reflects a broader industry recognition that fragmented glucose and ketone monitoring adds unnecessary friction for the people who depend on it daily. VivaChek’s Blood Glucose and β-Ketone Dual System demonstrates that auto coding, small sample volumes, wide hematocrit tolerance, and optional Bluetooth connectivity can be engineered into a single device without sacrificing the linearity and agreement metrics that matter for result reliability. For individuals managing diabetes, metabolic health, or ketosis risk, the practical recommendation is to evaluate dual-testing systems not only on test speed or sample size alone, but on the full specification set—hematocrit range, environmental tolerance, calibration method, and data connectivity—since these factors collectively determine real-world usability across different users and conditions.
https://www.vivachek.com
Hangzhou Weice Biotech Co., Ltd.